Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial Average jumped 1.13 percent to close at 25,826.43, while the S&P 500 Index inc...
Global Blood Therapeutics ( GBT +55.7% ) is up on more than an 8x surge in volume on the heels of positive data from a Phase 3 clinical trial, HOPE , evaluating voxelotor in patients at least 12 years old with sickle cell disease (SCD). The results were presented at ASH in San Diego. ...
FDA agrees with Global Blood Therapeutics' (NASDAQ: GBT ) proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). More news on: Global Blood Therapeutics, Healthcare stocks news, Read more ...
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today a...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to provide a regulatory update for voxelotor tomorrow, Monday, December 3, 2018, at 8:30 a.m. ET...
Global Blood Therapeutics (NASDAQ: GBT ): Q3 GAAP EPS of -$0.83 beats by $0.03. Cash and cash equivalents of $194.89M Press Release More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news,
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter ended September 30, 2018. “Voxelotor has the potential to be a transformative treatm...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation committee of the Company’s board of directors granted seven new employees options to purc...
Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). I have one model portfolio of my top biotech stocks focused on conviction ideas with in...
Company to Present Three Oral Presentations, Including Results Beyond 12 Weeks from Part A of the HOPE Study Company to Host Investor Webcast on Monday, December 3 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) toda...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...